Cooper, Brendan

Profile Picture
Biography
Brendan Cooper is Consultant Clinical Scientist and Hon. Professor in Respiratory Physiology at University Hospitals Birmingham and the University of Birmingham. He has over 40 years’ experience in both clinical and research practice in all aspects of lung function testing. He heads a large team of 50+ clinical physiologists across 5 hospital sites and has published over 180 peer-reviewed papers in respiratory physiology and is passionate about Quality Diagnostic lung function testing. He has been a member of several recent ATS/ERS Technical Standards Task Forces on lung function testing and is currently Co-Chair of the Global Lung Initiative for lung function reference values. He has been awarded; ARTP Award for Services to Respiratory Medicine 2017, AHCS Chair’s Award 2019, NHS England CSO Awards Healthcare Scientist of the Year in 2020, ERS Educational Award 2022. My research interests are wide ranging within respiratory physiology but usually evaluation of respiratory and sleep diagnostics and validation for respiratory diagnostics are the main themes.

Filters

2021 - 20246
Reset filters

Settings

Citations

Publication Search Results

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Publication
    Increase in recruitment upon integration of trial into a clinical care pathway: an observational study.
    (BMJ Publishing Group, 2021-07) Yip, Kay Por; Gompertz, Simon; Snelson, Catherine; Willson, Jeremy; Madathil, Shyam; Huq, Syed Sa; Rauf, Farrukh; Salmon, Natasha; Tengende, Joyce; Tracey, Julie; Cooper, Brendan; Filby, Kay; Ball, Simon; Parekh, Dhruv; Dosanjh, Davinder P S; Medical; Respiratory Medicine; Trauma and Orthopaedics; Outpatient Department; Physiotherapy; Allied Health Professional; Medical and Dental; Nursing and Midwifery Registered; Yip, Kay Por; Gompertz, Simon; Madathil, Shyam; Rauf, Farrukh; Salmon, Natasha; Tengende, Joyce; Cooper, Brendan; Filby, Kay
    Introduction: Many respiratory clinical trials fail to reach their recruitment target and this problem exacerbates existing funding issues. Integration of the clinical trial recruitment process into a clinical care pathway (CCP) may represent an effective way to significantly increase recruitment numbers. Methods: A respiratory support unit and a CCP for escalation of patients with severe COVID-19 were established on 11 January 2021. The recruitment process for the Randomised Evaluation of COVID-19 Therapy-Respiratory Support trial was integrated into the CCP on the same date. Recruitment data for the trial were collected before and after integration into the CCP. Results: On integration of the recruitment process into a CCP, there was a significant increase in recruitment numbers. Fifty patients were recruited over 266 days before this process occurred whereas 108 patients were recruited over 49 days after this process. There was a statistically significant increase in both the proportion of recruited patients relative to the number of COVID-19 hospital admissions (change from 2.8% to 9.1%, p<0.0001) and intensive therapy unit admissions (change from 17.8% to 50.2%, p<0.001) over the same period, showing that this increase in recruitment was independent of COVID-19 prevalence. Discussion: Integrating the trial recruitment process into a CCP can significantly boost recruitment numbers. This represents an innovative model that can be used to maximise recruitment without impacting on the financial and labour costs associated with the running of a respiratory clinical trial.
  • No Thumbnail Available
    Publication
    Measurement of breathing in patients with post-COVID-19 using structured light plethysmography (SLP).
    (BMJ Publishing Group, 2021-10) Alhuthail, Eyas; Stockley, James; Coney, Andrew; Cooper, Brendan; Outpatient Department; Medical and Dental; Stockley, James; Cooper, Brendan
    Introduction: COVID-19 pandemic has had a huge impact on global health to date, with 5.6 million cases in the UK since its emergence. The respiratory symptoms largely mimic those of pneumonia' with symptoms ranging from mild to severe. The effects on respiratory physiology are not yet fully understood, but evidence is emerging that there is much dysfunctional breathing reported but little information on tidal ventilation from the acute phase of the infection. Structured light plethysmography (SLP) is a contactless technique of respiratory function testing that measures tidal breathing parameters by assessing thoracoabdominal displacement. Methods: In a postdischarge clinic, SLP was performed routinely on 110 hospitalised patients recovering from COVID-19 who had been screened for respiratory symptoms to confirm any respiratory changes occurring after the disease. Patients were categorised based on their hospital treatment in (1) the intensive therapy unit (ITU) (requiring intubation) (n=65) or (2) respiratory wards only (n=45). Data from these two patient cohorts were compared with preacquired data from healthy controls (n=30). Results: We have found a significantly increased respiratory rate (p=0.006) in ITU patients compared with the healthy cohort and also a significant decrease in the inspiratory time (p=0.01), expiratory time (p=0.005) and the total breathing cycle (p=0.008). There were no significant differences between ITU and ward patients and no significant differences in healthy compared with ward patients. We examined the variability of breathing ('entropy') both in terms of the breath-to-breath interval and the volume-to-volume change. The breath-to-breath interval alone was significantly lower in ITU patients compared with healthy cohorts (p=0.02). Conclusion: Our findings suggest that abnormalities in tidal breathing can be detected in COVID-19 recovery patients, and SLP may be a promising tool in assessing the aftermath of diseases such as COVID-19, particularly if more intensive management strategies such as mechanical ventilation are required.
  • No Thumbnail Available
    Publication
    ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children.
    (European Respiratory Society, 2023-01-06) Riha, Renata L; Celmina, Marta; Cooper, Brendan; Hamutcu-Ersu, Refika; Kaditis, Athanasios; Morley, Andrew; Pataka, Athanasia; Penzel, Thomas; Roberti, Luca; Ruehland, Warren; Testelmans, Dries; van Eyck, Annelies; Grundström, Gert; Verbraecken, Johan; Randerath, Winfried; Lung Function and Sleep; Medical and Dental; Cooper, Brendan
    For more than three decades, type III devices have been used in the diagnosis of sleep disordered breathing in supervised as well as unsupervised settings. They have satisfactory positive and negative predictive values for detecting obstructive and central sleep apnoea in populations with moderately high pre-test probability of symptoms associated with these events. However, standardisation of commercially available type III devices has never been undertaken and the technical specifications can vary widely. None have been subjected to the same rigorous processes as most other diagnostic modalities in the medical field. Although type III devices do not include acquisition of electroencephalographic signals overnight, the minimum number of physical sensors required to allow for respiratory event scoring using standards outlined by the American Academy of Sleep Medicine remains debatable. This technical standard summarises data on type III studies published since 2007 from multiple perspectives in both adult and paediatric sleep practice. Most importantly, it aims to provide a framework for considering current type III device limitations in the diagnosis of sleep disordered breathing while raising research- and practice-related questions aimed at improving our use of these devices in the present and future.
  • No Thumbnail Available
    Publication
    Community-based intervention for prevention and management of chronic obstructive pulmonary disease in Nepal (COBIN-P trial): study protocol for a cluster-randomized controlled trial.
    (BioMed Central, 2021-07-21) Adhikari, Tara Ballav; Neupane, Dinesh; Karki, Arjun; Drews, Arne; Cooper, Brendan; Högman, Marieann; Sigsgaard, Torben; Kallestrup, Per; Outpatient Department; Healthcare Scientists; Cooper, Brendan
    Background: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and the commonest of non-communicable diseases (NCDs) in Nepal. Risk factors like indoor and outdoor air pollution, a high prevalence of smoking, and the lack of awareness of COPD make it a serious public health concern. However, no attempt has been made in Nepal to estimate its burden and address the disease at the community level. Method: This study aims to evaluate the effect of a community-based health educational intervention administered by Female Community Health Volunteers (FCHVs) on the prevention and management of COPD. An open-label, two-group, community-based, cluster-randomized controlled trial will be implemented in the semi-urban area of Pokhara Metropolitan city (former Lekhnath Municipality) located in the Kaski district of Nepal. The estimated sample size of the intervention will be 1143. The unit of randomization is the ward (administrative unit) of the study area. The follow-up survey will be conducted immediately after 12 months of FCHVs-led interventions. The difference in the rate of decline of forced expiratory volume in 1 s (FEV1) and FEV1/FVC (forced vital capacity) ratio are the primary outcomes and the change in the proportion of modifiable risk factors of COPD, health-related quality of life scores, and change in knowledge of COPD will be secondary outcomes. Discussion: This study will estimate the burden of COPD, the magnitude of risk factors and generate evidence to mobilize community health workers for COPD prevention and management at the community level in Nepal. Trial registration: ClinicalTrials.gov NCT03797768 . Registered on January 9, 2019.
  • No Thumbnail Available
    Publication
    Feasibility of a pulmonary rehabilitation programme for patients with symptomatic chronic obstructive pulmonary disease in Georgia: a single-site, randomised controlled trial from the Breathe Well Group.
    (BMJ Publishing Group, 2022-09-23) Maglakelidze, Mariam; Kurua, Ia; Maglakelidze, Nino; Maglakelidze, Tamaz; Chkhaidze, Ivane; Gogvadze, Ketevan; Chkhaidze, Natia; Beadle, Helen; Redden-Rowley, Kelly; Adab, Peymane; Adams, Rachel; Chi, Chunhua; Cheng, K K; Cooper, Brendan; Correia-de-Sousa, Jaime; Dickens, Andrew P; Enocson, Alexandra; Farley, Amanda; Gale, Nicola K; Jowett, Sue; Martins, Sonia; Rai, Kiran; Sitch, Alice J; Stavrikj, Katarina; Stelmach, Rafael; Turner, Alice M; Williams, Sian; Jordan, Rachel E; Jolly, Kate; Georgian Respiratory Association; Petre Shotadze Tbilisi Medical Academy; Ivane Javakhishvili Tbilisi State University Faculty of Medicine; Sandwell and West Birmingham NHS Trust; iCares; Lung Investigation; Allied Health Professional; Medical and Dental; Redden-Rowley, Kelly; Cooper, Brendan
    Feasibility of the intervention and RCT were assessed according to: study recruitment, consent and follow-up, intervention fidelity, adherence and acceptability, using questionnaires and measurements at baseline, programme end and 6 months, and through qualitative interviews.
  • No Thumbnail Available
    Publication
    Is lung function in a race against time?
    (Wiley-Blackwell, 2024-05-03) Cooper, Brendan; Stanojevic, Sanja; Lung Function and Sleep; Medical and Dental; Cooper, Brendan
    No abstract available